| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 51 | 2020 | 877 | 10.54 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 24 | 2020 | 1573 | 3.55 | Why? |
| Bridged Bicyclo Compounds, Heterocyclic | 9 | 2020 | 77 | 2.49 | Why? |
| Pyrimidines | 14 | 2020 | 1557 | 1.90 | Why? |
| Chromosome Deletion | 6 | 2019 | 62 | 1.71 | Why? |
| Quinazolinones | 8 | 2019 | 135 | 1.70 | Why? |
| Protein Kinase Inhibitors | 8 | 2019 | 1585 | 1.55 | Why? |
| Sulfonamides | 9 | 2020 | 1294 | 1.34 | Why? |
| Antineoplastic Agents | 14 | 2019 | 3550 | 1.31 | Why? |
| Bendamustine Hydrochloride | 4 | 2018 | 41 | 1.27 | Why? |
| Neoplasm, Residual | 6 | 2018 | 147 | 1.27 | Why? |
| Pyrazoles | 12 | 2020 | 1791 | 1.22 | Why? |
| Purines | 8 | 2019 | 816 | 1.22 | Why? |
| Tumor Suppressor Protein p53 | 6 | 2019 | 310 | 1.14 | Why? |
| Adenine | 12 | 2020 | 463 | 1.08 | Why? |
| Vidarabine | 6 | 2018 | 59 | 1.05 | Why? |
| Smith-Magenis Syndrome | 3 | 2018 | 5 | 0.96 | Why? |
| Receptors, Antigen, B-Cell | 4 | 2019 | 424 | 0.96 | Why? |
| Piperidines | 13 | 2020 | 795 | 0.87 | Why? |
| Chromosomes, Human, Pair 11 | 2 | 2019 | 16 | 0.86 | Why? |
| Rituximab | 8 | 2020 | 1096 | 0.79 | Why? |
| Quinazolines | 2 | 2018 | 126 | 0.72 | Why? |
| Immunotherapy | 7 | 2018 | 2421 | 0.68 | Why? |
| Cyclophosphamide | 5 | 2018 | 387 | 0.66 | Why? |
| Fever of Unknown Origin | 1 | 2018 | 93 | 0.65 | Why? |
| Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 176 | 0.63 | Why? |
| Disease-Free Survival | 7 | 2019 | 1654 | 0.56 | Why? |
| Thalidomide | 1 | 2017 | 247 | 0.56 | Why? |
| Inappropriate Prescribing | 1 | 2018 | 284 | 0.55 | Why? |
| Ataxia Telangiectasia Mutated Proteins | 3 | 2018 | 48 | 0.53 | Why? |
| Molecular Targeted Therapy | 5 | 2019 | 1579 | 0.51 | Why? |
| Antibodies, Monoclonal, Humanized | 10 | 2020 | 9335 | 0.48 | Why? |
| B-Lymphocytes | 6 | 2019 | 4418 | 0.47 | Why? |
| Cell Proliferation | 2 | 2019 | 1973 | 0.47 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 2 | 2018 | 1261 | 0.43 | Why? |
| Family Practice | 1 | 2018 | 472 | 0.43 | Why? |
| Chromosomes, Human, Pair 17 | 5 | 2018 | 13 | 0.42 | Why? |
| Maintenance Chemotherapy | 4 | 2018 | 133 | 0.41 | Why? |
| Immunoglobulin Heavy Chains | 4 | 2018 | 222 | 0.39 | Why? |
| Leukemia, Prolymphocytic, T-Cell | 2 | 2018 | 4 | 0.38 | Why? |
| Multiple Myeloma | 1 | 2019 | 1064 | 0.38 | Why? |
| Germany | 17 | 2020 | 9196 | 0.37 | Why? |
| Neoplasm Recurrence, Local | 5 | 2019 | 1063 | 0.37 | Why? |
| Leukemia, Myeloid, Acute | 3 | 2020 | 676 | 0.35 | Why? |
| Hematologic Neoplasms | 2 | 2019 | 2105 | 0.35 | Why? |
| Palliative Care | 3 | 2019 | 2665 | 0.34 | Why? |
| Leukemia, B-Cell | 2 | 2017 | 50 | 0.34 | Why? |
| Somatic Hypermutation, Immunoglobulin | 2 | 2017 | 283 | 0.32 | Why? |
| Prognosis | 12 | 2020 | 32490 | 0.32 | Why? |
| Lymphoma, B-Cell | 2 | 2019 | 166 | 0.31 | Why? |
| Transplantation Conditioning | 2 | 2019 | 323 | 0.31 | Why? |
| Remission Induction | 4 | 2018 | 950 | 0.29 | Why? |
| Treatment Outcome | 22 | 2019 | 51732 | 0.29 | Why? |
| Bone Marrow | 2 | 2018 | 492 | 0.28 | Why? |
| Hematopoietic Stem Cell Transplantation | 4 | 2020 | 2426 | 0.28 | Why? |
| Algorithms | 3 | 2019 | 7346 | 0.27 | Why? |
| Physical Fitness | 1 | 2007 | 334 | 0.27 | Why? |
| Clinical Trials as Topic | 7 | 2019 | 7330 | 0.26 | Why? |
| Humans | 99 | 2021 | 930598 | 0.26 | Why? |
| Alemtuzumab | 4 | 2018 | 121 | 0.26 | Why? |
| Models, Biological | 2 | 2018 | 4907 | 0.26 | Why? |
| Survival Analysis | 6 | 2018 | 7592 | 0.25 | Why? |
| Antibodies, Monoclonal, Murine-Derived | 2 | 2015 | 94 | 0.25 | Why? |
| Esophageal Neoplasms | 2 | 2018 | 357 | 0.25 | Why? |
| Drug Resistance, Neoplasm | 5 | 2018 | 447 | 0.25 | Why? |
| Dependovirus | 2 | 2010 | 272 | 0.24 | Why? |
| Immunoglobulin Variable Region | 3 | 2018 | 253 | 0.24 | Why? |
| Induction Chemotherapy | 3 | 2018 | 149 | 0.24 | Why? |
| Medical Oncology | 4 | 2018 | 3826 | 0.23 | Why? |
| Protein-Tyrosine Kinases | 3 | 2017 | 158 | 0.23 | Why? |
| Mutation | 10 | 2019 | 12376 | 0.23 | Why? |
| Lymphoma | 1 | 2007 | 522 | 0.23 | Why? |
| Emergency Medical Services | 1 | 2018 | 3557 | 0.22 | Why? |
| Administration, Oral | 3 | 2018 | 2340 | 0.21 | Why? |
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 127 | 0.21 | Why? |
| Geriatric Assessment | 2 | 2018 | 1372 | 0.21 | Why? |
| Abnormal Karyotype | 1 | 2019 | 6 | 0.21 | Why? |
| Tumor Microenvironment | 2 | 2019 | 264 | 0.21 | Why? |
| Paramyxoviridae Infections | 2 | 2020 | 364 | 0.21 | Why? |
| Receptor, Notch1 | 1 | 2019 | 21 | 0.20 | Why? |
| Gene Expression Regulation, Leukemic | 2 | 2017 | 31 | 0.20 | Why? |
| Neoplasms | 6 | 2019 | 17251 | 0.20 | Why? |
| Aged | 34 | 2021 | 215776 | 0.20 | Why? |
| Drug Administration Schedule | 3 | 2019 | 2324 | 0.19 | Why? |
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 29 | 0.19 | Why? |
| Martial Arts | 1 | 2018 | 31 | 0.19 | Why? |
| Karyotyping | 1 | 2018 | 52 | 0.19 | Why? |
| Cytotoxins | 1 | 2018 | 57 | 0.18 | Why? |
| Molecular Chaperones | 1 | 2019 | 124 | 0.18 | Why? |
| Breast Cancer Lymphedema | 1 | 2018 | 18 | 0.18 | Why? |
| Lamin Type B | 1 | 2017 | 5 | 0.18 | Why? |
| CD18 Antigens | 1 | 2017 | 19 | 0.18 | Why? |
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2017 | 9 | 0.18 | Why? |
| NFATC Transcription Factors | 1 | 2017 | 22 | 0.18 | Why? |
| Signal Transduction | 5 | 2019 | 7207 | 0.18 | Why? |
| Transplantation, Haploidentical | 1 | 2017 | 53 | 0.18 | Why? |
| Deubiquitinating Enzyme CYLD | 1 | 2017 | 9 | 0.18 | Why? |
| fms-Like Tyrosine Kinase 3 | 1 | 2017 | 43 | 0.18 | Why? |
| Gene Fusion | 1 | 2017 | 25 | 0.18 | Why? |
| beta 2-Microglobulin | 1 | 2017 | 102 | 0.17 | Why? |
| Combined Modality Therapy | 5 | 2019 | 3395 | 0.17 | Why? |
| Antigens, CD20 | 1 | 2018 | 105 | 0.17 | Why? |
| Female | 43 | 2021 | 380317 | 0.17 | Why? |
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2018 | 120 | 0.17 | Why? |
| Telomere Homeostasis | 1 | 2017 | 52 | 0.17 | Why? |
| Societies, Medical | 3 | 2018 | 6907 | 0.17 | Why? |
| Evidence-Based Medicine | 3 | 2018 | 3228 | 0.17 | Why? |
| Genes, Tumor Suppressor | 1 | 2017 | 43 | 0.17 | Why? |
| Esophagectomy | 1 | 2018 | 76 | 0.17 | Why? |
| Middle Aged | 36 | 2021 | 270681 | 0.17 | Why? |
| Antigens, Neoplasm | 2 | 2017 | 230 | 0.17 | Why? |
| Male | 40 | 2021 | 367725 | 0.17 | Why? |
| Germ-Line Mutation | 1 | 2017 | 86 | 0.17 | Why? |
| Peripheral Blood Stem Cell Transplantation | 1 | 2017 | 86 | 0.17 | Why? |
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2017 | 76 | 0.17 | Why? |
| Receptors, Adrenergic, beta-2 | 1 | 1997 | 32 | 0.17 | Why? |
| Antibodies, Monoclonal | 5 | 2018 | 8041 | 0.17 | Why? |
| CD40 Antigens | 1 | 2017 | 118 | 0.17 | Why? |
| Kaplan-Meier Estimate | 5 | 2018 | 4260 | 0.16 | Why? |
| RNA Splicing | 1 | 2017 | 119 | 0.16 | Why? |
| Aged, 80 and over | 16 | 2021 | 88759 | 0.16 | Why? |
| Nuclear Proteins | 1 | 2019 | 321 | 0.16 | Why? |
| Small Cell Lung Carcinoma | 1 | 2018 | 133 | 0.16 | Why? |
| Lassa Fever | 1 | 2017 | 88 | 0.16 | Why? |
| Neoplasm Staging | 3 | 2018 | 1999 | 0.16 | Why? |
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 347 | 0.16 | Why? |
| Lymphoma, Mantle-Cell | 2 | 2017 | 109 | 0.15 | Why? |
| Antibody-Dependent Cell Cytotoxicity | 1 | 2018 | 349 | 0.15 | Why? |
| Biomarkers, Tumor | 4 | 2017 | 1314 | 0.15 | Why? |
| Telomere | 1 | 2017 | 146 | 0.15 | Why? |
| Nitrogen Mustard Compounds | 1 | 2015 | 4 | 0.15 | Why? |
| Breast Neoplasms | 3 | 2018 | 3633 | 0.15 | Why? |
| DNA Damage | 1 | 2018 | 285 | 0.15 | Why? |
| Bevacizumab | 1 | 2017 | 149 | 0.15 | Why? |
| Proto-Oncogene Proteins | 1 | 2018 | 340 | 0.15 | Why? |
| Peripheral Nervous System Diseases | 1 | 2018 | 193 | 0.15 | Why? |
| Cell-Free Nucleic Acids | 1 | 2018 | 271 | 0.15 | Why? |
| Diagnosis, Differential | 3 | 2021 | 7220 | 0.15 | Why? |
| Medical Overuse | 1 | 2017 | 146 | 0.14 | Why? |
| Pulmonary Aspergillosis | 1 | 2020 | 408 | 0.14 | Why? |
| Survival Rate | 4 | 2017 | 9206 | 0.14 | Why? |
| Cell Line, Tumor | 6 | 2018 | 3608 | 0.14 | Why? |
| Genetic Testing | 1 | 2018 | 395 | 0.14 | Why? |
| B7-H1 Antigen | 1 | 2018 | 541 | 0.14 | Why? |
| Genetic Association Studies | 1 | 2017 | 559 | 0.14 | Why? |
| DNA-Binding Proteins | 1 | 2017 | 469 | 0.14 | Why? |
| Angiogenesis Inhibitors | 1 | 2018 | 395 | 0.14 | Why? |
| Imatinib Mesylate | 1 | 2017 | 327 | 0.14 | Why? |
| Virus Activation | 1 | 2019 | 480 | 0.13 | Why? |
| Eosinophilia | 1 | 2017 | 292 | 0.13 | Why? |
| Plasmodium falciparum | 1 | 2017 | 337 | 0.13 | Why? |
| Vascular Endothelial Growth Factor A | 1 | 2018 | 604 | 0.13 | Why? |
| Genetic Predisposition to Disease | 3 | 2018 | 4027 | 0.13 | Why? |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 314 | 0.13 | Why? |
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 502 | 0.13 | Why? |
| Thymidine Kinase | 1 | 1992 | 11 | 0.13 | Why? |
| Exosomes | 1 | 2019 | 567 | 0.12 | Why? |
| Viremia | 1 | 2020 | 1020 | 0.12 | Why? |
| Immunophenotyping | 1 | 2018 | 1290 | 0.12 | Why? |
| Advance Care Planning | 1 | 2019 | 426 | 0.12 | Why? |
| Antibodies, Neoplasm | 2 | 2009 | 15 | 0.12 | Why? |
| Malaria, Falciparum | 1 | 2017 | 377 | 0.12 | Why? |
| Lymphoma, Non-Hodgkin | 2 | 1996 | 403 | 0.12 | Why? |
| Patient Selection | 1 | 2007 | 4560 | 0.12 | Why? |
| Chronic Disease | 1 | 2007 | 5139 | 0.12 | Why? |
| Adenosine Monophosphate | 2 | 2020 | 5652 | 0.12 | Why? |
| Alanine | 2 | 2020 | 5687 | 0.12 | Why? |
| DNA Methylation | 1 | 2017 | 688 | 0.12 | Why? |
| Costs and Cost Analysis | 1 | 2017 | 694 | 0.12 | Why? |
| Lymph Nodes | 1 | 2019 | 1060 | 0.12 | Why? |
| Quality Assurance, Health Care | 1 | 2017 | 596 | 0.12 | Why? |
| Transcription Factors | 1 | 2017 | 784 | 0.11 | Why? |
| Genetic Therapy | 1 | 1996 | 409 | 0.11 | Why? |
| Epigenesis, Genetic | 1 | 2018 | 711 | 0.11 | Why? |
| Phospholipases A2 | 1 | 2010 | 33 | 0.11 | Why? |
| Hepatitis B virus | 1 | 2019 | 882 | 0.11 | Why? |
| Recurrence | 2 | 2019 | 3675 | 0.11 | Why? |
| Internal Medicine | 1 | 2017 | 557 | 0.11 | Why? |
| Intersectoral Collaboration | 1 | 2018 | 1065 | 0.11 | Why? |
| Hepatitis B | 1 | 2019 | 888 | 0.10 | Why? |
| Oncologists | 1 | 2017 | 877 | 0.10 | Why? |
| Lung Neoplasms | 2 | 2018 | 3228 | 0.10 | Why? |
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2009 | 28 | 0.10 | Why? |
| Interdisciplinary Communication | 1 | 2018 | 1425 | 0.10 | Why? |
| Adult | 21 | 2020 | 244371 | 0.10 | Why? |
| Clinical Trials, Phase III as Topic | 3 | 2018 | 782 | 0.10 | Why? |
| Gastrointestinal Tract | 1 | 2018 | 1113 | 0.10 | Why? |
| Age Factors | 4 | 2018 | 21039 | 0.10 | Why? |
| NF-kappa B | 1 | 2017 | 1301 | 0.10 | Why? |
| Graft vs Host Disease | 3 | 2019 | 501 | 0.10 | Why? |
| Health Care Costs | 1 | 2018 | 1007 | 0.10 | Why? |
| Genetic Vectors | 1 | 1996 | 1600 | 0.09 | Why? |
| Exercise Therapy | 1 | 2018 | 976 | 0.09 | Why? |
| Health Priorities | 1 | 2017 | 959 | 0.09 | Why? |
| Patient Care Management | 1 | 2020 | 1514 | 0.09 | Why? |
| Animals | 10 | 2019 | 78931 | 0.09 | Why? |
| Melanoma | 1 | 2019 | 1229 | 0.09 | Why? |
| Civil Defense | 1 | 2020 | 1687 | 0.09 | Why? |
| Time Factors | 4 | 2020 | 31397 | 0.09 | Why? |
| Killer Cells, Natural | 1 | 2018 | 2093 | 0.09 | Why? |
| Exercise | 2 | 2018 | 6771 | 0.09 | Why? |
| Patient Isolation | 1 | 2021 | 3182 | 0.09 | Why? |
| Capsid Proteins | 1 | 2010 | 365 | 0.09 | Why? |
| Tumor Cells, Cultured | 2 | 2017 | 254 | 0.08 | Why? |
| Follow-Up Studies | 5 | 2020 | 17020 | 0.08 | Why? |
| Endosomes | 1 | 2010 | 490 | 0.08 | Why? |
| Proportional Hazards Models | 1 | 2019 | 6543 | 0.08 | Why? |
| Disease Progression | 4 | 2019 | 13580 | 0.08 | Why? |
| Hospitals, University | 1 | 2019 | 4173 | 0.08 | Why? |
| Disease Management | 3 | 2019 | 6841 | 0.08 | Why? |
| Consensus | 2 | 2017 | 6345 | 0.07 | Why? |
| Allografts | 2 | 2020 | 761 | 0.07 | Why? |
| Liver Neoplasms | 1 | 2017 | 1666 | 0.07 | Why? |
| Drug Design | 1 | 2017 | 2627 | 0.07 | Why? |
| Clinical Trials, Phase II as Topic | 2 | 2018 | 801 | 0.07 | Why? |
| Autoimmune Diseases | 1 | 2018 | 1996 | 0.07 | Why? |
| Mice | 6 | 2019 | 21357 | 0.07 | Why? |
| Antirheumatic Agents | 1 | 2019 | 3023 | 0.07 | Why? |
| Dose-Response Relationship, Drug | 2 | 2017 | 3776 | 0.07 | Why? |
| Fear | 1 | 2019 | 3607 | 0.06 | Why? |
| Mice, Inbred C57BL | 3 | 2019 | 5542 | 0.06 | Why? |
| T-Lymphocytes | 2 | 2018 | 6670 | 0.06 | Why? |
| Gene Frequency | 2 | 2018 | 1210 | 0.06 | Why? |
| Colorectal Neoplasms | 1 | 2017 | 1884 | 0.06 | Why? |
| Disease Models, Animal | 2 | 2018 | 10998 | 0.06 | Why? |
| Risk Factors | 5 | 2020 | 71621 | 0.06 | Why? |
| DNA Mutational Analysis | 2 | 2018 | 581 | 0.06 | Why? |
| Influenza Vaccines | 1 | 2018 | 2941 | 0.06 | Why? |
| Virion | 1 | 2010 | 1444 | 0.06 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.06 | Why? |
| Cardiology | 1 | 2017 | 2873 | 0.06 | Why? |
| Aging | 1 | 2018 | 3581 | 0.06 | Why? |
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 1014 | 0.05 | Why? |
| IgG Deficiency | 1 | 2020 | 22 | 0.05 | Why? |
| Communication | 1 | 2019 | 5206 | 0.05 | Why? |
| E1A-Associated p300 Protein | 1 | 2019 | 8 | 0.05 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.05 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.05 | Why? |
| Sialoglycoproteins | 1 | 2019 | 24 | 0.05 | Why? |
| Galactose | 1 | 2020 | 201 | 0.05 | Why? |
| Acetylation | 1 | 2019 | 124 | 0.05 | Why? |
| Busulfan | 1 | 2019 | 22 | 0.05 | Why? |
| Risk Assessment | 3 | 2020 | 25439 | 0.05 | Why? |
| Whole-Body Irradiation | 1 | 2019 | 42 | 0.05 | Why? |
| Mitoxantrone | 1 | 2018 | 30 | 0.05 | Why? |
| Postoperative Complications | 1 | 2018 | 5861 | 0.05 | Why? |
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2018 | 10 | 0.05 | Why? |
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2018 | 13 | 0.05 | Why? |
| Vinca Alkaloids | 1 | 2018 | 2 | 0.05 | Why? |
| Hepatitis B Core Antigens | 1 | 2019 | 76 | 0.05 | Why? |
| Mannans | 1 | 2020 | 218 | 0.05 | Why? |
| Mice, Inbred NOD | 1 | 2018 | 134 | 0.05 | Why? |
| Voriconazole | 1 | 2020 | 206 | 0.05 | Why? |
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 45 | 0.05 | Why? |
| Travel | 1 | 2017 | 7220 | 0.05 | Why? |
| HEK293 Cells | 3 | 2019 | 8394 | 0.05 | Why? |
| Cell Cycle | 1 | 2019 | 329 | 0.05 | Why? |
| Prospective Studies | 3 | 2019 | 43301 | 0.04 | Why? |
| Organoplatinum Compounds | 1 | 2018 | 76 | 0.04 | Why? |
| Naphthalenes | 1 | 2018 | 94 | 0.04 | Why? |
| CD5 Antigens | 1 | 2017 | 3 | 0.04 | Why? |
| Cell Transformation, Neoplastic | 1 | 2019 | 191 | 0.04 | Why? |
| Chromatin Immunoprecipitation | 1 | 2017 | 53 | 0.04 | Why? |
| Heterografts | 1 | 2018 | 203 | 0.04 | Why? |
| Neoplasms, Second Primary | 1 | 2018 | 100 | 0.04 | Why? |
| Togo | 1 | 2017 | 95 | 0.04 | Why? |
| Colforsin | 1 | 1997 | 4 | 0.04 | Why? |
| DNA, Protozoan | 1 | 2017 | 77 | 0.04 | Why? |
| Dasatinib | 1 | 2017 | 55 | 0.04 | Why? |
| Collagen Type IV | 1 | 2017 | 12 | 0.04 | Why? |
| Chromosome Aberrations | 1 | 2017 | 54 | 0.04 | Why? |
| Isoproterenol | 1 | 1997 | 31 | 0.04 | Why? |
| Chemotaxis | 1 | 2017 | 67 | 0.04 | Why? |
| Germ Cells | 1 | 2017 | 39 | 0.04 | Why? |
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 130 | 0.04 | Why? |
| Cholera Toxin | 1 | 1997 | 27 | 0.04 | Why? |
| Genomic Instability | 1 | 2017 | 80 | 0.04 | Why? |
| Phenylurea Compounds | 1 | 2018 | 101 | 0.04 | Why? |
| Leukocytes, Mononuclear | 2 | 2018 | 2115 | 0.04 | Why? |
| Unrelated Donors | 1 | 2018 | 187 | 0.04 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.04 | Why? |
| Immunogenetics | 1 | 2017 | 124 | 0.04 | Why? |
| ADP-ribosyl Cyclase 1 | 1 | 2017 | 96 | 0.04 | Why? |
| Diagnosis-Related Groups | 1 | 2018 | 167 | 0.04 | Why? |
| Metapneumovirus | 1 | 2020 | 465 | 0.04 | Why? |
| Contact Tracing | 1 | 2017 | 8448 | 0.04 | Why? |
| Telomere Shortening | 1 | 2017 | 66 | 0.04 | Why? |
| Immunoblotting | 1 | 2017 | 180 | 0.04 | Why? |
| Pyelonephritis | 1 | 2017 | 66 | 0.04 | Why? |
| Cyclic AMP | 1 | 1997 | 76 | 0.04 | Why? |
| Retrospective Studies | 8 | 2021 | 105322 | 0.04 | Why? |
| Hepatitis B Surface Antigens | 1 | 2019 | 305 | 0.04 | Why? |
| Antigen-Presenting Cells | 1 | 2017 | 206 | 0.04 | Why? |
| Clinical Trials, Phase I as Topic | 1 | 2018 | 242 | 0.04 | Why? |
| Lymphoma, Follicular | 1 | 2017 | 109 | 0.04 | Why? |
| Xenograft Model Antitumor Assays | 1 | 2017 | 274 | 0.04 | Why? |
| Waldenstrom Macroglobulinemia | 1 | 2017 | 85 | 0.04 | Why? |
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2017 | 121 | 0.04 | Why? |
| Molecular Typing | 1 | 2017 | 280 | 0.04 | Why? |
| MicroRNAs | 1 | 2009 | 1787 | 0.04 | Why? |
| Granulomatous Disease, Chronic | 1 | 1996 | 60 | 0.04 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.04 | Why? |
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2021 | 581 | 0.04 | Why? |
| Gene Expression Profiling | 2 | 2018 | 3788 | 0.04 | Why? |
| Interleukin-1beta | 1 | 2021 | 992 | 0.04 | Why? |
| Triazoles | 1 | 2020 | 440 | 0.04 | Why? |
| Interleukin-4 | 1 | 2017 | 367 | 0.04 | Why? |
| Ubiquitination | 1 | 2017 | 343 | 0.04 | Why? |
| Survivors | 2 | 2018 | 2619 | 0.04 | Why? |
| Bias | 1 | 2021 | 1109 | 0.04 | Why? |
| Gene Transfer Techniques | 1 | 1996 | 134 | 0.04 | Why? |
| Extracellular Matrix | 1 | 2017 | 189 | 0.04 | Why? |
| Tomography, X-Ray Computed | 2 | 2020 | 25144 | 0.04 | Why? |
| Cross Infection | 1 | 2017 | 8675 | 0.04 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.04 | Why? |
| Benzamides | 1 | 2018 | 421 | 0.04 | Why? |
| Nitriles | 1 | 2020 | 1053 | 0.04 | Why? |
| Drug Synergism | 1 | 2018 | 833 | 0.04 | Why? |
| Yoga | 1 | 2018 | 189 | 0.04 | Why? |
| Resistance Training | 1 | 2018 | 273 | 0.04 | Why? |
| Gender Identity | 1 | 2017 | 262 | 0.04 | Why? |
| Genetic Diseases, Inborn | 1 | 1996 | 190 | 0.04 | Why? |
| Probability | 1 | 2019 | 923 | 0.04 | Why? |
| Salvage Therapy | 1 | 2017 | 417 | 0.03 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.03 | Why? |
| Neovascularization, Pathologic | 1 | 2018 | 305 | 0.03 | Why? |
| Inflammasomes | 1 | 2021 | 710 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2019 | 15421 | 0.03 | Why? |
| Pyridines | 1 | 2020 | 680 | 0.03 | Why? |
| Quinolines | 1 | 2018 | 403 | 0.03 | Why? |
| Promoter Regions, Genetic | 1 | 2017 | 823 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.03 | Why? |
| Influenza, Human | 1 | 2018 | 10779 | 0.03 | Why? |
| Phosphorylation | 1 | 2017 | 1060 | 0.03 | Why? |
| Statistics, Nonparametric | 1 | 1997 | 1008 | 0.03 | Why? |
| beta-Thalassemia | 1 | 1996 | 200 | 0.03 | Why? |
| Vincristine | 1 | 2012 | 89 | 0.03 | Why? |
| Patients | 1 | 2020 | 1167 | 0.03 | Why? |
| Cell Division | 1 | 1992 | 136 | 0.03 | Why? |
| Myeloproliferative Disorders | 1 | 2017 | 507 | 0.03 | Why? |
| Neoplasm Proteins | 1 | 2018 | 501 | 0.03 | Why? |
| Extracellular Vesicles | 1 | 2019 | 607 | 0.03 | Why? |
| Mice, Knockout | 1 | 2017 | 1815 | 0.03 | Why? |
| Hospitals, Teaching | 1 | 2020 | 1609 | 0.03 | Why? |
| Hematologic Diseases | 1 | 2018 | 614 | 0.03 | Why? |
| Interleukins | 1 | 2017 | 762 | 0.03 | Why? |
| Lung | 1 | 2020 | 31049 | 0.03 | Why? |
| Cell Survival | 1 | 2017 | 1581 | 0.03 | Why? |
| Receptors, Antigen, T-Cell | 1 | 2017 | 760 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2018 | 2437 | 0.03 | Why? |
| Forecasting | 2 | 2017 | 4492 | 0.03 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 2309 | 0.03 | Why? |
| Chemokines | 1 | 2017 | 1095 | 0.03 | Why? |
| Serotyping | 1 | 2010 | 154 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Hematology | 1 | 2017 | 649 | 0.03 | Why? |
| Mice, Transgenic | 1 | 2018 | 2739 | 0.03 | Why? |
| Intention to Treat Analysis | 1 | 2012 | 673 | 0.03 | Why? |
| Thorax | 1 | 2020 | 1873 | 0.03 | Why? |
| Doxorubicin | 1 | 2012 | 313 | 0.03 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2017 | 830 | 0.03 | Why? |
| Standard of Care | 1 | 2017 | 1297 | 0.02 | Why? |
| Israel | 1 | 2019 | 2751 | 0.02 | Why? |
| CD52 Antigen | 1 | 2008 | 6 | 0.02 | Why? |
| Risk Management | 1 | 2017 | 1044 | 0.02 | Why? |
| Antifungal Agents | 1 | 2020 | 1828 | 0.02 | Why? |
| Pharmacokinetics | 1 | 2008 | 41 | 0.02 | Why? |
| Regression Analysis | 1 | 1997 | 2484 | 0.02 | Why? |
| Macrophages | 1 | 2021 | 2784 | 0.02 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2018 | 10649 | 0.02 | Why? |
| Physical Therapy Modalities | 1 | 2018 | 1090 | 0.02 | Why? |
| Anemia | 1 | 1996 | 789 | 0.02 | Why? |
| Membrane Proteins | 1 | 2019 | 1733 | 0.02 | Why? |
| Phosphoproteins | 1 | 2019 | 4346 | 0.02 | Why? |
| Administration, Cutaneous | 1 | 2009 | 229 | 0.02 | Why? |
| Peptide Fragments | 1 | 2019 | 2075 | 0.02 | Why? |
| Dendritic Cells | 1 | 2017 | 1330 | 0.02 | Why? |
| Cancer Care Facilities | 1 | 2017 | 1190 | 0.02 | Why? |
| Vascular Diseases | 1 | 2017 | 846 | 0.02 | Why? |
| Infection Control | 1 | 2017 | 23131 | 0.02 | Why? |
| Adolescent | 2 | 2019 | 86841 | 0.02 | Why? |
| Immunoglobulins, Intravenous | 1 | 2020 | 2705 | 0.02 | Why? |
| Prednisone | 1 | 2012 | 652 | 0.02 | Why? |
| Hemorrhage | 1 | 2020 | 3013 | 0.02 | Why? |
| Double-Blind Method | 1 | 2019 | 5988 | 0.02 | Why? |
| Lymphocyte Activation | 1 | 2017 | 2742 | 0.02 | Why? |
| Genomics | 1 | 2019 | 3118 | 0.02 | Why? |
| Precision Medicine | 1 | 2017 | 1477 | 0.02 | Why? |
| Pyrazines | 1 | 2018 | 1783 | 0.02 | Why? |
| Quality of Life | 2 | 2018 | 9820 | 0.02 | Why? |
| Monocytes | 1 | 2019 | 2978 | 0.02 | Why? |
| HeLa Cells | 1 | 2010 | 1303 | 0.02 | Why? |
| Incidence | 2 | 2019 | 25622 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3633 | 0.02 | Why? |
| Lung Diseases | 1 | 2020 | 2361 | 0.02 | Why? |
| Seasons | 1 | 2018 | 4071 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2017 | 6049 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2019 | 7268 | 0.02 | Why? |
| Leukopenia | 1 | 2006 | 280 | 0.02 | Why? |
| Cause of Death | 1 | 2018 | 4823 | 0.02 | Why? |
| Lymphocytes | 1 | 2017 | 3056 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.02 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.02 | Why? |
| Immunity, Cellular | 1 | 2017 | 3614 | 0.02 | Why? |
| Glycoproteins | 1 | 2008 | 615 | 0.02 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.02 | Why? |
| Chi-Square Distribution | 1 | 2006 | 961 | 0.02 | Why? |
| Antigens, CD | 1 | 2008 | 984 | 0.02 | Why? |
| Treatment Failure | 1 | 2009 | 2106 | 0.02 | Why? |
| Comorbidity | 1 | 2007 | 34796 | 0.02 | Why? |
| Immunity, Innate | 1 | 2021 | 6570 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2020 | 8248 | 0.01 | Why? |
| Europe | 1 | 2019 | 12702 | 0.01 | Why? |
| Clinical Competence | 1 | 2017 | 3263 | 0.01 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.01 | Why? |
| Ultrasonography | 1 | 2017 | 4409 | 0.01 | Why? |
| Triage | 1 | 2020 | 7151 | 0.01 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2018 | 43792 | 0.01 | Why? |
| Primary Health Care | 1 | 2018 | 4839 | 0.01 | Why? |
| Hospitals | 1 | 2018 | 11793 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Multivariate Analysis | 1 | 2006 | 5440 | 0.01 | Why? |
| Cohort Studies | 1 | 2019 | 36005 | 0.01 | Why? |
| Anti-Infective Agents | 1 | 2006 | 1766 | 0.01 | Why? |
| Virus Diseases | 1 | 1992 | 3779 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| United States | 1 | 2019 | 46150 | 0.01 | Why? |
| HIV Infections | 1 | 1996 | 11620 | 0.01 | Why? |
| Quarantine | 1 | 2017 | 18418 | 0.01 | Why? |
| Young Adult | 1 | 2019 | 93724 | 0.01 | Why? |
| Hospitalization | 1 | 2018 | 54280 | 0.01 | Why? |
| Respiratory Tract Infections | 1 | 2006 | 6817 | 0.00 | Why? |